J&J-Pharmacyclics drug shows potential in high-risk leukemia patients

February 17, 2015 3:29 PM

16 0

(Reuters) - Pharmacyclics Inc said its cancer drug developed with a Johnson & Johnson unit improved overall response rate in high-risk leukemia patients.

Those administered with Imbruvica showed an overall response rate of 88 percent, while 76.6 percent survived without the disease getting worse at 24 months.

Read more

To category page